DRD2 Partial Agonists Market: Competitive Landscape, Pipeline, and Market Analysis 2023

Purchase Option

$ 4400
$ 6600
$ 8900

Dopamine receptor D2 (DRD2) is a protein-coupled by a G protein-coupled receptor. DRD2 autoreceptor activation protects dopamine neurons from cell death, and D2R mediates cognitive flexibility in humans. DRD2 partial agonists act by mediating an intermediate level of dopaminergic neuronal tone between full agonist and antagonist of the D2 receptor, and the partial agonism allows the drugs to stimulate D2 receptors under low dopamine conditions while attenuating their activation when dopamine levels are high. DRD2 Partial Agonists are indicated for DRD1 antagonists are used in the treatment of schizophrenia, management of acute manic or mixed episodes in patients with bipolar I disorder, major depression, post-traumatic stress disorder, generalized anxiety disorder, psychosis associated with Parkinson’s disease, and others. Gedeon Richter, BMS, AbbVie, Seelos Therapeutics, Otsuka Pharmaceutical, Jiangsu Kanion Pharma, and Reviva Pharmaceuticals are major players in the DRD2 partial agonists market.

Approved Drug Molecules and Brand Names for DRD2 Partial Agonists:

  • Aripiprazole
  • Rexulti (Brexpiprazole)
  • Vraylar (Cariprazine)
  • Abilify Maintena (Aripiprazole depot formulation)
  • Abilify MyCite (Aripiprazole tablets embedded with sensor)
  • Brexpiprazole QW (OPC-34712 once weekly)
  • Abilify Asimtufii (Aripiprazole two-month)

Drugs under the Pipeline for DRD2 Partial Agonists:

  • Pardoprunox (SLV-308)
  • Aplindore (SLS-006)
  • TPN-672
  • Brilaroxazine (RP5063)
  • JX11502MA

Key Market Developments:

  • In Jun 2023, Otsuka Pharmaceutical announced its intention to submit regulatory filings to PMDA (Pharmaceuticals and Medical Devices Agency) for Agitation Associated with Dementia due to Alzheimer's Disease for Rexulti (brexpiprazole).
  • In Jun 2023, AbbVie announced reimbursement under the Non-Insured Health Benefits (NIHB) Program for Cariprazine for the treatment of schizophrenia in Canada.

Clinical Activity and Developments of DRD2 Partial Agonists:

Currently, there are 12 drug products in the DRD2 partial agonists, including seven approved drug products and the rest of them are in the clinical development phases.

  • In Apr 2023, Otsuka Pharmaceutical released safety and pharmacokinetics data from a phase-I trial in bipolar disorder and schizophrenia for Aripiprazole.
  • In May 2023, Reviva Pharmaceuticals released pharmacodynamics data from a preclinical trial in idiopathic pulmonary fibrosis for Brilaroxazine.

Molecule Name

Number of Studies

Pardoprunox (SLV-308)

13

Aplindore (SLS-006)

4

TPN-672

2

Brilaroxazine (RP5063)

2

JX11502MA

1

 

Target Indication Analysis of DRD2 Partial Agonists

DRD2 partial agonists such as Aripiprazole, Cariprazine, and Brexpiprazole are indicated in the treatment of conditions such as autistic disorder, bipolar disorders, Tourette’s syndrome, major depressive disorder, and Schizophrenia. DRD2 partial agonists are also in the clinical investigational phases for agitation, pervasive child development disorders, post-traumatic stress disorders, attention-deficit hyperactivity disorder, and others.

Key Features of the Reports

  • The report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments, and start-up details that are actively working in the market
  • The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario

Frequently Asked Questions

Aripiprazole, Rexulti (Brexpiprazole), Vraylar (Cariprazine), and Abilify Maintena (Aripiprazole depot formulation) are some of the approved DRD2 partial agonists.

Gedeon Richter, BMS, AbbVie, Seelos Therapeutics, Otsuka Pharmaceutical, Jiangsu Kanion Pharma, and Reviva Pharmaceuticals are some of the major players in the DRD2 partial agonists market.

Major indications for DRD2 partial agonists are autistic disorder, bipolar disorders, Tourette’s syndrome, major depressive disorder, and Schizophrenia.

There are a total of five molecules in the clinical development phases for DRD2 partial agonists.

  • Gedeon Richter
  • BMS
  • AbbVie
  • Seelos Therapeutics
  • Otsuka Pharmaceutical
  • Jiangsu Kanion Pharma
  • Reviva Pharmaceuticals
  • Zhejiang Jingxin Pharma

Adjacent Markets